Search Results

Business

n-Lorem Foundation Announces Partnership with Nitto Avecia to Strengthen Development of Personalized Medicines for Patients with Ultra-Rare Diseases

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients with ultra-rare diseases, today announced a new partnership with Nitto Avecia, the world’s largest oligonucleotide therapeutics manufacturer.

June 16, 2021

·

4 min read

Deals

Nitto Acquires Bend Labs, Inc. in the United States

Nitto Denko Corporation (headquarter: Osaka, Japan, President: Hideo Takasaki, hereafter Nitto) (TOKYO:6988) and Bend Labs, Inc. (US, Co-CEO: Jared Jonas, Colton Ottley, hereafter “Bend”) have agreed on Nitto’s acquisition of Bend.

June 1, 2022

·

2 min read

Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business

In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc.

March 31, 2021

·

3 min read

Business

New President Appointed for Nitto Avecia Inc.

Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.

August 3, 2018

·

2 min read

Genetown

Nitto Avecia Completes Multiple Successful Oligonucleotide Manufacturing Synthesis Runs at 1.6 Mol Scale

This exciting news comes only months after bringing into operation Avecia’s new API manufacturing synthesis capabilities.

November 7, 2017

·

1 min read

Business

Nitto Avecia Pharma Services Appoints Raymond Kaczmarek as President

Mr. Kaczmarek joins the organization with nearly 20 years of extensive experience in operations management within the pharmaceutical and biopharmaceutical industries.

January 15, 2018

·

2 min read

Nitto BioPharma Inc.

Nitto BioPharma Inc. offers unique drug and nucleic acid (siRNA, miRNA, mRNA, etc) delivery solutions by designing novel biodegradable delivery vehicles with the combined ability to target specific cells and efficiently deliver a therapeutic moiety to the cells.

June 17, 2024

Business

Avecia Announces Opening of Cambridge, MA Office

Avecia announced today the opening of a new corporate office in Cambridge, MA, to support its operations and corporate development activities, and to be more accessible to clients.

February 1, 2018

·

1 min read

Genetown

Nitto Denko Avecia Inc. Announces Multiple Oligonucleotide Expansions

November 14, 2016

·

3 min read

Deals

Nitto Denko Avecia Inc. Acquires The Businesses Of Irvine Pharmaceutical Services, Inc. & Avrio Biopharmaceuticals

October 12, 2016

·

2 min read